A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study

Blood
Shuichi MiyawakiRyuzo Ohno

Abstract

We conducted a prospective randomized study to assess the optimal postremission therapy for adult acute myeloid leukemia in patients younger than 65 years in the first complete remission. A total of 781 patients in complete remission were randomly assigned to receive consolidation chemotherapy of either 3 courses of high-dose cytarabine (HiDAC, 2 g/m(2) twice daily for 5 days) alone or 4 courses of conventional standard-dose multiagent chemotherapy (CT) established in the previous JALSG AML97 study. Five-year disease-free survival was 43% for the HiDAC group and 39% for the multiagent CT group (P = .724), and 5-year overall survival was 58% and 56%, respectively (P = .954). Among the favorable cytogenetic risk group (n = 218), 5-year disease-free survival was 57% for HiDAC and 39% for multiagent CT (P = .050), and 5-year overall survival was 75% and 66%, respectively (P = .174). In the HiDAC group, the nadir of leukocyte counts was lower, and the duration of leukocyte less than 1.0 × 10(9)/L longer, and the frequency of documented infections higher. The present study demonstrated that the multiagent CT regimen is as effective as our HiDAC regimen for consolidation. Our HiDAC regimen resulted in a beneficial effect on disease-fr...Continue Reading

References

Jul 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W R VoglerP L Banks
Apr 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P A CassilethM J O'Connell
Jul 26, 2002·British Journal of Haematology·Alan K BurnettUNKNOWN Medical Research Council Adult and Paediatric Working Parties
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Jan 15, 2005·Proceedings of the National Academy of Sciences of the United States of America·Yue-Ying WangSai-Juan Chen
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter PaschkaUNKNOWN Cancer and Leukemia Group B

❮ Previous
Next ❯

Citations

Jul 25, 2012·International Journal of Hematology·Takuya MatsunagaKazuya Shimoda
Dec 10, 2013·Hematology·Peter Paschka, Konstanze Döhner
May 6, 2014·Current Treatment Options in Oncology·Peter H Wiernik
Aug 21, 2013·Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·Noriko Usui
Aug 2, 2012·International Journal of Hematology·Shuichi Miyawaki
May 15, 2013·Current Hematologic Malignancy Reports·Nicholas D Reese, Gary J Schiller
Mar 20, 2015·Der Internist·K DöhnerH Döhner
Sep 29, 2011·Blood·Edo VellengaUNKNOWN Swiss Group for Clinical Cancer Research Collaborative Group (SAKK)
Feb 26, 2011·Blood·Eric J Feldman
Jan 17, 2015·Current Opinion in Hematology·Ofir Wolach, Richard M Stone
Feb 20, 2015·Hematology·Konstanze Döhner, Peter Paschka
Feb 22, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xavier ThomasHervé Dombret
May 1, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Markus SchaichGerhard Ehninger
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mei GuoHui-Sheng Ai
Dec 4, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roelof WillemzeTheo de Witte
Jul 31, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hubert ServeWolfgang E Berdel
Apr 4, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kenneth F BradstockUNKNOWN Australasian Leukaemia & Lymphoma Group
Jan 23, 2017·International Journal of Hematology·Taiki AndoUNKNOWN Yokohama Cooperative Study Group for Hematology (YACHT)
Apr 26, 2017·British Journal of Haematology·Yasuyuki AraiUNKNOWN Japan Society for Haematopoietic Cell Transplantation
Aug 28, 2018·Current Opinion in Hematology·Bo CaiHuisheng Ai
Apr 23, 2014·European Journal of Haematology·Hiroaki ShimizuYoshihisa Nojima

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.